EP300 and prostate carcinoma: Both HOXB13K13A mutants and parental cells displayed similar levels of sensitivity to the CBP/p300 inhibitor A-485 or GNE-049 (Figure 2D; Supplementary Figure S4C,D), suggesting that in prostate cancer, HOXB13 lysine 13 acetylation confers a therapeutic vulnerability to DNA-damaging therapies.